NASDAQ:PTPI Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis $0.0050 0.00 (0.00%) As of 07/2/2026 03:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Petros Pharmaceuticals Stock (NASDAQ:PTPI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Petros Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0050▼$0.006050-Day Range$0.0050▼$0.008052-Week Range$0.00▼$0.04Volume100,565 shsAverage Volume103,170 shsMarket Capitalization$155.80 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. Read More Receive PTPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTPI Stock News HeadlinesFinancial Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) versus MindWalk (NASDAQ:HYFT)June 25, 2026 | americanbankingnews.comPetros Pharmaceuticals Delays Annual 10-K FilingMarch 31, 2026 | tipranks.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Petros Pharmaceuticals grants significant RSUs to key leadersJanuary 3, 2026 | msn.comPetros Pharmaceuticals to be Delisted from NasdaqNovember 7, 2025 | msn.comPetros Pharmaceuticals Inc (PTPI) - Investing.comSeptember 6, 2025 | investing.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company ...June 26, 2025 | finanznachrichten.dePetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | MorningstarJune 26, 2025 | morningstar.comMSee More Headlines PTPI Stock Analysis - Frequently Asked Questions How have PTPI shares performed this year? Petros Pharmaceuticals' stock was trading at $0.0071 at the start of the year. Since then, PTPI stock has decreased by 29.6% and is now trading at $0.0050. How were Petros Pharmaceuticals' earnings last quarter? Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($8.46) earnings per share for the quarter. When did Petros Pharmaceuticals' stock split? Shares of Petros Pharmaceuticals reverse split before market open on Thursday, May 1st 2025.The 1-25 reverse split was announced on Tuesday, April 29th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Petros Pharmaceuticals? Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Petros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/15/2025Today7/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTPI CIK1815903 Webwww.petrospharma.com Phone973-242-0005FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.16 million Net MarginsN/A Pretax Margin-117.50% Return on Equity-78.22% Return on Assets-23.50% Debt Debt-to-Equity Ratio1.58 Current Ratio0.85 Quick Ratio0.74 Sales & Book Value Annual Sales$5.11 million Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.00Miscellaneous Outstanding Shares31,160,000Free Float9,932,000Market Cap$155.80 thousand OptionableNot Optionable Beta1.86 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:PTPI) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredElon Musk on His New Invention: “An Infinite Money Glitch.”Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...Chaikin Analytics | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron, Unocal, and Texaco each confirmed the same energy technology worked - no fuel costs, no carb...Behind the Markets | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
